[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reproductive-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reproductive-health":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,62,90,119,147,175,222,243,265,339,376,404],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100509219","improving-alcohol-and-substance-use-care-access-outcome-equity-during-the-reproductive-years-100509219",false,"NCT05910580","Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years","Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics","Inclusion Criteria:\n\n* Over the age of 18 years\n* U.S. residing\n* Have internet access (own a computer or smart phone)\n* Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments\n\nExclusion Criteria:\n\n* Not capable of communicating (reading, speaking, writing) in English or Spanish","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic.\n\nThe main questions it aims to answer are:\n\n* Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing?\n* Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity?\n* Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)?\n\nParticipants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months.\n\nResearchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.",[26,27,28,29,30,31,32,33,34,35],"Alcohol-Related Disorders","Substance-Related Disorders","Mental Health","Reproductive Health","Sexual Health","Sexually Transmitted Diseases","Contraception","Maternal Health","Pregnancy","Women's Health",[37,38,39,40,41,42,43,44,45,46,47,48],"Implementation Science","Mass Screening","Motivational Interviewing","Referral and Consultation","Quality of Health Care","Early Medical Intervention","Family Planning Services","Primary Health Care","Reproductive Health Services","Telemedicine","Preconception Care","Young Adult","RECRUITING","2026-06-12",{"date":52,"type":53},"2026-06-15","ACTUAL",{"date":55,"type":53},"2025-07-03",{"date":57,"type":20},"2027-05-31",{"name":59,"class":60},"Emory University","OTHER",4,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100643029","gansu-nurses-health-cohort-study-100643029","NCT07645911","Gansu Nurses' Health Cohort Study","Gansu Nurses' Health Surveillance and Improvement Action Program","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Able to communicate freely, have the ability to act, and agree to participate in this study.\n\nExclusion Criteria:\n\n1. Resigned from the hospital;\n2. Without a nursing license;\n3. Have a history of mental illness or severe cognitive impairment.",true,{"count":71,"type":20},1000,"OBSERVATIONAL","This study aims to understand the health status, work stress, and occupational exposure in the work environment among nurses in Gansu Province, China. We will collect information through questionnaires and conduct follow-up surveys every two years. The results of this study will help improve working conditions for nurses in the future and provide scientific evidence for developing health protection policies for the nursing workforce.",[75,28,76,77,29],"Nurses' Occupational Health","Chronic Diseases","Occupational Exposure",[79,80,81],"Nurses, Occupational Health, Questionnaire Survey","Nurse health status","Nurse Health Cohort Study","NOT_YET_RECRUITING","2026-06-10",{"date":50,"type":53},{"date":83,"type":20},{"date":87,"type":20},"2032-12-31",{"name":89,"class":60},"LanZhou University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":69,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100556435","health-e-you-efficacy-trial-for-male-adolescents-100556435","NCT06525064","Health-E You Efficacy Trial for Male Adolescents","Health-E You\u002FSalud iTu: Pre-visit Mobile Health App for Male Adolescents to Promote Adolescent-centered Sexual & Reproductive Healthcare Receipt","Inclusion Criteria:\n\n* Assigned male sex at birth\n* Age 13 to 21 years old\n* English and\u002For Spanish as preferred language to read, listen, and converse\n* Self-reported engagement in vaginal and\u002For anal sex in the past 12 months\n* Access to phone or internet for follow-up study activities\n\nExclusion Criteria:\n\n* Aged 12 or younger or older than 21\n* Primary language other than English or Spanish\n* Not able to provide informed consent\n* Unable to communicate due to cognitive, mental, language, or other difficulties\n* Not sexually active, engaged in oral sex only, or more than 12 months have passed since last vaginal and\u002For anal sex.\n* Previous participation in a Health-E You study activity or the app","MALE","13 Years","21 Years",{"count":101,"type":20},2752,[23],"This study will involve evaluating Health-E You\u002FSalud ìTu™, a web-based, pre-visit mobile app designed to support adolescent male youth and his clinicians in discussing sexual and reproductive health (SRH) topics and care. It will test its efficacy among male patients in clinical settings using a stepped wedge cluster randomized controlled trial design.",[31,30,29],[106,107,108],"male adolescent","condom use","mhealth","2026-06-03",{"date":111,"type":53},"2026-06-05",{"date":113,"type":53},"2026-06-02",{"date":115,"type":20},"2027-12",{"name":117,"class":60},"Johns Hopkins University",8,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":127,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100638840","early-prevention-and-precision-management-of-female-fertility-decline-100638840","NCT07581444","Early Prevention and Precision Management of Female Fertility Decline","Development and Evaluation of a Precision Prevention Strategy for Early Female Fertility Decline Based on OvaRePred-Plus: A Multicenter Cluster Randomized Controlled Trial","OvaRePred-Plus","Inclusion Criteria:\n\n* Women aged 20-40 years\n* Diagnosed with infertility or planning assisted reproductive treatment\n* Regular menstrual cycles (21-35 days)\n* Willing to participate in a 12-week lifestyle intervention program\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Known chromosomal abnormalities or genetic disorders affecting fertility\n* History of ovarian surgery or severe ovarian damage\n* Diagnosed endocrine disorders affecting reproduction (e.g., uncontrolled thyroid disease, hyperprolactinemia)\n* Severe systemic diseases (e.g., cardiovascular, hepatic, renal diseases)\n* Current pregnancy or breastfeeding\n* Use of hormonal medications or supplements affecting ovarian function within the past 3 months\n* Participation in another clinical trial within the past 3 months","FEMALE","20 Years","40 Years",{"count":131,"type":20},384,[23],"Female fertility decline has become an important public health issue in China, with a substantial proportion of women of reproductive age experiencing reduced ovarian reserve. However, effective tools for early identification and large-scale prevention of fertility impairment in the general population are still lacking.\n\nThis study aims to develop and evaluate a precision prevention strategy for early female fertility decline based on the OvaRePred-Plus model, which integrates ovarian reserve markers, lifestyle factors, and reproductive health indicators. A multicenter, cluster randomized controlled trial will be conducted across six medical centers in China, enrolling women aged 20-40 years identified as having early signs of fertility decline.\n\nParticipants will be allocated to either an intervention group receiving a comprehensive health management program (including dietary optimization, nutritional supplementation, physical activity, and sleep improvement) or a control group receiving routine clinical care. The intervention will last for 12 weeks.\n\nThe primary outcome is the change in fertility score assessed by the OvaRePred-Plus model. Secondary outcomes include changes in ovarian reserve markers (e.g., AMH), menstrual status, ultrasound parameters, and reproductive outcomes.\n\nThis study is expected to provide evidence for a scalable and cost-effective strategy for early prevention and management of female fertility decline.",[135,136,29,137],"Female Fertility Decline","Diminished Ovarian Reserve","Infertility Prevention","2026-05-06",{"date":140,"type":53},"2026-05-12",{"date":142,"type":20},"2026-06",{"date":144,"type":20},"2026-12",{"name":146,"class":60},"Peking University Third Hospital",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":69,"sex":127,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100568698","integrating-prep-decision-making-into-counseling-in-sexual-and-reproductive-health-clinics-100568698","NCT06684613","Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics","Project Carmenta: Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics","Patients (inclusion):\n\n* Woman\n* Aged 18 years or older\n* Have a uterus\n* Do not have HIV (by self-report)\n* Not currently on PrEP\n* Comfortable conversing in English or Spanish\n* Able to participate in informed consent procedures\n\nPatients (exclusion):\n\n* People who cannot become pregnant (i.e., have had a hysterectomy or tubal ligation)\n* People who wish to become pregnant (will not qualify for pregnancy prevention counseling)\n* Have a scheduled visit with a member of the investigative team (to minimize risk of potential ascertainment bias)\n* Participants of Aim 1 cannot participate in Aim 2.\n\nSexual and Reproductive Health clinicians will be included if they provide sexual and reproductive health patient care at any of the participating sites. Clinic staff will be included if they work at any of the participating sites and have patient-facing or non-patient-facing roles .",{"count":155,"type":20},50,[23],"This study addresses the need for HIV prevention to be integrated into counseling visits at sexual and reproductive health clinics.",[159,29],"Sexual Risk Behavior for HIV-infection",[161,162,163,164],"HIV Prevention","PrEP","sexual reproductive health","woman","2026-03-17",{"date":167,"type":53},"2026-03-19",{"date":169,"type":53},"2026-03-11",{"date":171,"type":20},"2027-09-05",{"name":173,"class":60},"Yale University",1,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":182,"enrollmentInfo":183,"targetDuration":185,"studyType":72,"phases":4,"briefSummary":186,"conditions":187,"keywords":200,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":174},"100616933","long-term-evaluation-of-fertility-preservation-options-in-women-in-cancer-remission-or-haematological-pathology-100616933","NCT07312058","Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology","FERT-ISSUES","Inclusion Criteria:\n\n* Women\n* Aged between 18 and 47 years\n* Diagnosed with cancer or hematological disorders requiring potentially gonadotoxic treatment\n* Having undergone a medical fertility preservation consultation\n* Followed at Amiens Picardie University Hospital (CHU Amiens Picardie) in the department of Reproductive Medicine\n* Currently in remission\n* Having expressed non-opposition to participation in the study\n\nExclusion Criteria:\n\n* Absence of remission\n* Patients deprived of liberty by administrative or judicial decision, or placed under legal protection (guardianship or curators)\n* Decline to participate in the study","47 Years",{"count":184,"type":20},102,"1 Day","Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity.\n\nWomen of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.\n\nHowever, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission.\n\nThis project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies.\n\nThis work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU).\n\nIts objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care.\n\nThis work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.",[188,189,190,29,191,192,193,194,195,196,197,198,199],"Fertility Preservation","Cancer Remission","Reproductive Outcomes","Oncology","Fertility Counseling","Assisted Reproductive Technology","Psychological Impact","Fertility Observatory","Patient Follow-up","Female Cancer Survivors","Fertility Preservation Techniques","Live Birth Rate",[201,202,203,204,191,205,206,207,208,209,210,211,212],"Fertility preservation","Cancer remission","Reproductive outcomes","Reproductive health","Fertility counseling","Assisted reproductive technology","Psychological impact","Fertility observatory","Patient follow-up","Female cancer survivors","Fertility preservation techniques","Live birth rate","2026-01-15",{"date":215,"type":53},"2026-01-16",{"date":217,"type":20},"2025-12-17",{"date":219,"type":20},"2027-01",{"name":221,"class":60},"Centre Hospitalier Universitaire, Amiens",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":129,"enrollmentInfo":228,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":5},"100376615","effects-of-prior-induced-termination-of-pregnancy-on-complications-and-pregnancy-outcomes-100376615","NCT04183829","Effects of Prior Induced Termination of Pregnancy on Complications and Pregnancy Outcomes.","Inclusion Criteria:\n\n* women have induced abortion in early pregnancy (\\\u003C12 weeks of gestation).\n* permanent population and no tendency to move.\n* normal language expression and understanding ability, able to understand research content.\n* be able and willing to provide written informed consent and effective contact information, and be willing to cooperate with follow-up investigations.\n\nExclusion Criteria:\n\n* above the age of 40\n* with history of adverse pregnancy and childbirth",{"count":229,"type":20},20000,"A prospective multicenter cohort study to evaluate effects of prior induced termination of pregnancy on complications and pregnancy outcomes.",[29,232],"Abortion","2025-09-05",{"date":235,"type":53},"2025-09-12",{"date":237,"type":53},"2019-06-01",{"date":239,"type":20},"2028-06",{"name":241,"class":242},"National Research Institute for Family Planning, China","OTHER_GOV",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":250,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":174},"100588095","reproductive-and-mental-health-of-patients-with-aplastic-anemia-100588095","NCT06936930","Reproductive and Mental Health of Patients With Aplastic Anemia","A Study on Reproductive and Psychological Health in Aplastic Anemia Patients","Inclusion Criteria:\n\n* Diagnosis of AA\n* Male or female, aged 18-40 years\n* ECOG performance status ≤2\n* Willing and able to comply with the requirements for this study and written informed consent\n\nExclusion Criteria:\n\n* Diagnosis of inherited bone marrow failure syndromes\n* Combined with other hematological diseases\n* Chemotherapy-induced bone marrow failure\n* Pregnant or breastfeeding women\n* Subjects with a history of mental illness or severe psychological disorders\n* Subjects with a history of reproductive system cancer (eg, penile cancer, testicular cancer, prostate cancer, ovarian cancer, cervical cancer, vaginal cancer, etc.)\n* Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study",{"count":251,"type":20},600,"Aplastic anemia (AA) is a hematological disease characterized by bone marrow failure, leading to varying degrees of anemia, leukopenia, and thrombocytopenia. With the advancement of immunosuppressive therapy and hematopoietic stem cell transplantation, the survival of AA patients has significantly improved. However, these treatment approaches may result in reproductive system impairment.\n\nReproductive health has been a major concern among reproductive-age AA patients. In female patients, it often manifests as irregular menstruation, amenorrhea, and infertility; while in male patients, it may present as reduced sperm count and low sperm motility. The reproductive impairment observed in AA patients may be attributed to various factors, including the disease's underlying pathophysiology, side effects of used medications such as androgens and the toxicity conditioning agents during transplantation.\n\nNotably, immunosuppressive agents (such as cyclosporine and antithymocyte globulin) and chemotherapeutic drugs (such as cyclophosphamide) can suppress hematopoiesis and directly damage the gonads, thereby impairing reproductive function. Furthermore, long-term use of these medications may disrupt the endocrine system, affecting the secretion of sex hormones and overall reproductive capacity. Additionally, chronic anemia in AA patients can lead to compensatory physiological changes in other body systems, which may also indirectly affect reproductive health.",[254,29],"Aplastic Anemia",[254],"2025-07-31",{"date":258,"type":53},"2025-08-05",{"date":260,"type":53},"2025-03-03",{"date":262,"type":20},"2027-12-31",{"name":264,"class":60},"Institute of Hematology & Blood Diseases Hospital, China",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":69,"sex":16,"minAge":185,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":275,"conditions":276,"keywords":300,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":174},"100469557","generation-victoria-cohort-2020s-a-statewide-longitudinal-cohort-study-of-victorian-children-and-their-parents-100469557","NCT05394363","Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents","Generation Victoria Cohort 2020s. A Statewide Longitudinal Cohort of Victorian Children and Their Parents","GenV","Inclusion Criteria (Children):\n\n* Birth date between 4th October 2021 and 3rd October 2023\n* Live at the time of recruitment\n* Residing in Victoria at the time of recruitment\n* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the child's behalf, who provides a signed and dated informed consent form (e.g. a parent\u002Fguardian)\n\nInclusion Criteria (Adults):\n\n* Be a parent or guardian of a child who meets the eligibility criteria above\n* Provide a signed and dated informed consent form or have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.\n\nExclusion criteria:\n\n* Children who are deceased at the time of recruitment (i.e. still born or died after birth) and their parents\u002Fguardians\n* Families unable to provide informed consent in any of the languages available",{"count":274,"type":20},150000,"Generation Victoria (GenV) is a longitudinal, population-based study of Victorian children and their parents that will bring together data on a wide range of conditions ,exposures and outcomes. GenV blends study-collected, study-enhanced and linked data. It will be multi-purpose, supporting observational, interventional, health services and policy research within the same cohort. It is designed to address physical, mental and social issues experienced during childhood, as well as the antecedents of a wide range of diseases of ageing. It seeks to generate translatable evidence (prediction, prevention, treatments, services) to improve future wellbeing and reduce the future disease burden of children and adults.\n\nThe GenV Cohort 2020s is open to all children born over a two-year period, and their parents, residing in the state of Victoria Australia. The GenV Cohort 2020s is preceded by an Advance Cohort of children born between 5 Dec 2020 and 3 October 2021, and their parents. This comprises all families recruited at GenV's Vanguard hospital (Joan Kirner Women's and Children's) and at birthing hospitals throughout Victoria as GenV scaled up to commence recruiting for the GenV Cohort 2020s. The Advance Cohort have ongoing and full participation in GenV for their lifetime unless they withdraw but may have less complete data and biosamples.",[28,277,278,279,29,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299],"Child Wellbeing","Infant Health","Child Health","Healthy Aging","Health Equity","Quality of Life","Social Determinants of Health","Environmental Exposure","Genetics","Cognition","Learning","Child Development","Congenital Abnormalities","Disability","Injuries","Communicable Diseases","Noncommunicable Diseases","Physical Fitness","Diet","Obesity","Allergy and Immunology","Inflammation","Intergenerational Relations",[301,271,302,303,304,279,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,281,321,322,323,324,325,326,327,283,328,329],"Generation Victoria","Cohort Studies","Data Collection","Data Linkage","Midlife Health","Children","Infants","Family","Parents","Mothers","Fathers","Life course perspective","Population Health","Longitudinal Studies","Genetics, population","Demography","Epidemiology","Health Disparity","Minority Health","Vulnerable Populations","Clinical Trial","Randomized Controlled Trial","Pragmatic Clinical Trial","Health Services Research","Economic Models","Value of Life","Geographic Information Systems","Climate Change","Built Environment","2025-07-30",{"date":332,"type":53},"2025-08-03",{"date":334,"type":53},"2021-10-04",{"date":336,"type":20},"2033-10",{"name":338,"class":60},"Murdoch Childrens Research Institute",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":350,"conditions":351,"keywords":358,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":174},"100588716","monitoring-nutritional-consequences-of-obesity-treatment-on-womens-health-100588716","NCT06945016","Monitoring Nutritional Consequences of Obesity Treatment on Women's Health","MOnitoring NUtritional COnsequences of Obesity Treatment on Women's Health and Transgenerational Effects for Healthier Future Generations: a Multicentre Prospective Observational Cohort Study","MONUCO","General Inclusion Criteria:\n\n* Female sex at birth\n* Aged 18-55 years of age\n* Living with obesity (BMI ≥ 30 kg\u002Fm2)\n* Approved for obesity treatment in one of the participating hospitals:\n* Undergoing primary bariatric surgery (RYGB, OAGB or SG)\n* Receiving obesity medication (any type) with a BMI ≥30 kg\u002Fm2 under medical supervision.\n* For those undergoing MRI, DEXA and quantitative ultrasound scan: Willing to be informed about incidental findings of pathology and approving of reporting this to their general physician.\n\nAdditional inclusion criteria for birth cohort:\n\n* Being pregnant\n* Age 18-45 years of age\n* Having received prior obesity treatment, either surgical (RYGB, OAGB, SG) or pharmacological for at least 4 months under medical supervision (any type).\n\nGeneral Exclusion Criteria:\n\n* Male sex at birth\n* Aged \\\u003C18 or \\>55 years of age\n* BMI \\\u003C30 kg\u002Fm2\n* Not able to read and\u002For write in Dutch\n* Undergoing a revisional or secondary bariatric procedure (excluding previous gastric banding)\n* Malnutrition due to other chronic condition, specifically malignancy, substance abuse\n* (mental) condition that makes it impossible to fill out a questionnaire correctly.\n* For those undergoing a DEXA scan: height \\>196 cm or weight \\>160 kg\n* For those undergoing a MRI scan: having a contra-indication to MRI scanning including (but not limited to) pacemakers and defibrillators, intraorbital or intraocular metallic fragments, ferromagnetic implans or claustrophobia.\n\nAdditional exclusion criteria birth cohort:\n\n* Aged \\\u003C18 or \\>45 years of age\n* \\>25 weeks of gestation\n* Multiple pregnancy\n* Reversal of the bariatric procedure","55 Years",{"count":349,"type":20},1150,"The goal of this observational study is to investigate the long-term effect of obesity treatments on the health of women. This study will specifically focusses on the effects on nutritional intake, nutritional status, musculoskeletal health and reproductive health. Additionally, this study will also investigate the effect of obesity treatment on pregnancy outcomes and child development.\n\nTo achieve the goal of this study, participants already receiving either surgical treatment for obesity or treatment with anti-obesity medication as part of their regular medical care will fill in additional questionnaires, provide blood, urine and feces samples, and undergo additional measurements of body composition and muscle strength up to for 10 years.",[352,353,354,355,356,29,28,34,357],"Obesity and Obesity-related Medical Conditions","Bariatric Surgery","Anti-obesity Agents","Body Composition","Muscle Strength","Nutritional Status",[359,360,361,362,363,364,365,366],"cohort","obesity treatment","obesity","Bariatric surgery","anti-obesity agents","body composition","nutrition","observational","2025-07-06",{"date":369,"type":53},"2025-07-10",{"date":371,"type":53},"2025-01-28",{"date":373,"type":20},"2040-01-28",{"name":375,"class":60},"Wageningen University and Research",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":69,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":384,"conditions":385,"keywords":393,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":174},"100377597","apple-womens-health-study-100377597","NCT04196595","Apple Women's Health Study","Inclusion Criteria:\n\n* Have menstruated at least once\n* Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico)\n* Live in the United States of America\n* Be comfortable communicating in written and spoken English\n* Have installed the Apple Research app on your iPhone\n* Not share your iCloud account or iPhone with anyone else\n* Be willing and able to provide informed consent to participate in the study",{"count":383,"type":20},500000,"This is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including PCOS, infertility and breast cancer.The study will be hosted within the Research app(available on App Store), which allows a user to find, enroll, and participate in Apple-supported health-related research studies.",[386,387,388,389,390,391,392,29],"Menstrual Cycle","Ovulation","Menstruation","Polycystic Ovary Syndrome","Infertility","Menopause","Reproduction",[388,386,387,389,390,391,392,29],"2024-07-01",{"date":396,"type":53},"2024-07-03",{"date":398,"type":53},"2019-11-14",{"date":400,"type":20},"2029-11",{"name":402,"class":403},"Apple Inc.","INDUSTRY",{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":432},"100407263","ovarian-reserve-and-bariatric-surgery-100407263","NCT04583150","Ovarian Reserve and Bariatric Surgery","Evolution of Ovarian Reserve in Severely Obese Women After Bariatric Surgery","BARIAOVO","Inclusion Criteria:\n\nObese women with planned surgery (BS group)\n\n1. Obese women with an indication of bariatric surgery (BMI ≥ 35 kg\u002Fm² with an obesity related comorbidity or BMI ≥ 40 kg\u002Fm²)\n2. Age 18 to 37 years (inclusion possible until the day before the 37th birthday)\n3. No pregnancy project in the next 12 months\n4. Signed informed consent\n5. Affiliated to The French social security except patient on AME (state medical aid)\n\nObese women with no planned surgery (control group)\n\n1. Obese women with BMI ≥ 35 kg\u002Fm²\n2. Age 18 to 37 years (inclusion possible until the day before the 37th birthday)\n3. No pregnancy project in the next 12 months\n4. Signed informed consent\n5. Affiliated to the French social security except patient on AME (state medical aid)\n6. Matched for age and BMI category (35-39.9 kg\u002Fm², 40-49.9 kg\u002Fm² and ≥ 50 kg\u002Fm²) with an operated woman\n7. No bariatric surgery project in the next 12 months\n\nExclusion Criteria:\n\nFor both groups : Obese women with planned bariatric surgery (BS group) and obese women with no planned surgery (control group):\n\n1. Medical condition known to alter ovarian reserve (previous oophorectomy, ovarian surgery, chemotherapy, pelvis or hypothalamic radiotherapy, known premature ovarian insufficiency …)\n2. Contraceptive with antigonadotropic action during the month before inclusion\n3. Pregnant or lactating woman\n4. HIV infection\n5. Previous bariatric surgery\n6. Expected follow up less than 3 years\n7. Absolute contraindication for bariatric surgery (vital risk, anaesthetic contraindication, non stabilized psychiatric disorder, substance addiction)","37 Years",{"count":414,"type":20},238,"The expansion of the obesity epidemic is accompanied with an increase in bariatric procedures, in particular in women of reproductive age. Severe obesity has negative effects on fertility and on in vitro fertilization (IVF) outcomes, and the weight loss induced by the bariatric surgery (BS) is believed to reverse the deleterious impact of overweight and obesity on female fertility. However, research is limited to retrospective cohort studies, small case-series and case-control studies. Weight reduction has been shown to improve fecundity and hormonal state of a subgroup of obese patients with polycystic ovary syndrome (PCOS). In this population, recent studies have demonstrated an increase of naturally conceived pregnancies following bariatric surgery. However, these studies have evaluated only short-term evolution of ovarian function and not all studies demonstrated improvements in fertility outcomes after BS. Clearly, more studies are needed regarding the effect of BS on obesity-related infertility, and long-term outcome of ovarian function has to be assessed.\n\nMarkers of ovarian reserve, including Follicle Stimulating Hormone (FSH), antral follicle count (AFC), and anti-mullerian hormone (AMH), have been used to counsel patients regarding in their reproductive outcomes. Serum AMH concentrations remain remarkably stable throughout the menstrual cycle, which is a great advantage over other markers of fertility. Various studies have evaluated the association between AMH and body mass index (BMI) but reported contradictory results. Some of them have reported a significant inverse correlation between AMH and BMI, but others found no relationship between AMH and BMI. Scarce and small preliminary studies have been performed to evaluate AMH changes after surgical weight loss and showed a decrease in serum AMH.",[353,296,29,417],"Fertility",[296,362,419,420,417,421,422],"Gastric bypass","Sleeve","Anti-mullerian hormone","Ovarian reserve","2024-02-14",{"date":425,"type":53},"2024-02-15",{"date":427,"type":53},"2020-12-03",{"date":429,"type":20},"2028-03",{"name":431,"class":60},"Assistance Publique - Hôpitaux de Paris",14]